Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Clinical Trials
1.5k
Trial Phases
5 Phases
Drug Approvals
70
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
Distribution across different clinical trial phases (1396 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age
- Conditions
- Respiratory Syncytial Virus Immunization
- Interventions
- Biological: RSV vaccine formulation 1 doseBiological: RSV vaccine formulation 3 doseBiological: RSV vaccine formulation 8 doseBiological: RSV vaccine formulation 2 doseBiological: RSV vaccine formulation 4 doseBiological: RSV vaccine formulation 6 doseBiological: RSV vaccine formulation 7 doseBiological: RSV vaccine formulation 5 dose
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 240
- Registration Number
- NCT07071558
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 218
- Registration Number
- NCT07053423
Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 350
- Registration Number
- NCT07052396
Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)
- Conditions
- Type 1 Diabetes
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3500
- Registration Number
- NCT07038473
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT07007962
- Prev
- 1
- 2
- 3
- 4
- 5
- 294
- Next
News
Trogenix Strengthens Leadership Team with Key Clinical Appointments as Odysseus Platform Advances Toward Clinical Trials
Trogenix has appointed Atif Abbas, MD as Chief Medical Officer, bringing over 25 years of oncology drug development experience including successful IND submissions for immunotherapy compounds and regulatory approvals.
Thermo Fisher Scientific Acquires Sanofi's New Jersey Manufacturing Site to Expand U.S. Sterile Drug Production
Thermo Fisher Scientific will acquire Sanofi's sterile manufacturing facility in Ridgefield, New Jersey, expanding their strategic partnership to enhance U.S. drug product manufacturing capacity.
Sanofi's SAR446597 Gene Therapy Receives FDA Fast Track Designation for Geographic Atrophy Treatment
The US FDA has granted fast track designation to Sanofi's SAR446597, a one-time intravitreal gene therapy for treating geographic atrophy due to age-related macular degeneration.
Cipla Plans Entry into India's Weight Management Market as Obesity Becomes Strategic Priority
Cipla is preparing to enter India's weight management segment to address rising demand for effective obesity solutions, as announced by CEO Umang Vohra in the company's 2024-25 annual report.
Renasant Bio Raises $54.5M to Develop Novel Ion Channel Therapies for ADPKD
Renasant Bio secured $54.5 million in seed funding from investors including 5AM Ventures, Atlas Venture, OrbiMed and Qiming Venture Partners USA to develop treatments for autosomal dominant polycystic kidney disease (ADPKD).
Sanofi Advances Multiple Phase 2 Trials Targeting Rare Kidney Diseases and Ulcerative Colitis
Sanofi has initiated a Phase 2a clinical trial evaluating three experimental drugs—Frexalimab, SAR442970, and Rilzabrutinib—for treating primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) in patients aged 16 to 75 years.
Sanofi Launches Long-term Safety Study for TZIELD in Stage 2 Type 1 Diabetes Patients
Sanofi has initiated an observational study to evaluate the long-term safety and efficacy of TZIELD (teplizumab-mzwv) in patients with Stage 2 Type 1 Diabetes.
EPO and UPC Reach Opposite Conclusions on Amgen's PCSK9 Antibody Patent Validity
The European Patent Office (EPO) Opposition Division upheld Amgen's PCSK9 antibody patent EP 3666797, finding it inventive, while the Unified Patent Court (UPC) Central Division revoked the same patent for lacking inventive step.
bluebird bio Strengthens Leadership Team with Three Key Executive Appointments
bluebird bio, a pioneer in gene therapies for severe genetic diseases, has appointed three new executives to strengthen its leadership team as the company focuses on commercial execution.
ESTEVE Acquires Caprelsa Rights from Sanofi to Expand Rare Cancer Treatment Portfolio
ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries for treating aggressive and symptomatic medullary thyroid cancer in adults and children above 5 years of age.